Irritable Bowel Syndrome with Constipation
📧 Sign up to get email alerts when something new happens for Irritable Bowel Syndrome with Constipation.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-10-18Clinical Trial Update: GOS to Reduce Symptom Severity in IBS [NA]
A completed clinical trial sponsored by Clasado evaluated galacto-oligosaccharide (GOS) for reducing symptom severity in irritable bowel syn…
-
CLINICAL_TRIALS trial_result · 2024-10-18Clinical Trial Update: A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome [Phase 2]
A Phase 2 clinical trial evaluating ASP0456 in constipation-predominant irritable bowel syndrome (IBS-C) has completed. The update reports t…
-
CLINICAL_TRIALS trial_result · 2024-10-18Clinical Trial Update: Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
This is a completed post-marketing surveillance study evaluating the safety of Linaclotide tablets in patients with chronic constipation and…
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Evaluate the Safety of Linaclotide in IBS-C Patients in China
A completed clinical trial assessing the safety of Linaclotide in patients with irritable bowel syndrome with constipation (IBS-C) in China.
-
FDA approval · 2023-06-12FDA Approved: LINZESS — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Linzess (linaclotide) submitted by Allergan.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-03-23FDA Approved: LUBIPROSTONE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the original application for lubiprostone from Zydus Pharmaceuticals USA Inc., establishing a generic version of Lubiprostone. …
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) [Phase 2]
This trial update reports termination of the Phase 2 study of olorlinab for irritable bowel syndrome, including IBS with constipation and IB…
-
FDA label_change · 2022-04-05FDA Approved: IBSRELA — Supplemental Application (Ardelyx, Inc.)
FDA approved a supplemental application for IBSRELA (tenapanor hydrochloride) submitted by Ardelyx, updating the drug labeling.
-
FDA approval · 2022-01-18FDA Approved: LUBIPROSTONE — Original Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva's Lubiprostone generic under an original application (ANDA 209920). This marks approval of a generic version of lubipr…
-
CLINICAL_TRIALS trial_result · 2021-12-06Clinical Trial Update: A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C) [Phase 4]
Phase 4 trial update evaluating linaclotide's effect on abdominal girth in IBS-C; study terminated with results posted earlier.
-
CLINICAL_TRIALS trial_result · 2021-10-29Clinical Trial Update: Effect of Tai Chi as Treatment for IBS-C [NA]
Completed clinical trial investigating Tai Chi as a treatment for Irritable Bowel Syndrome with Constipation; results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: Efficacy and Safety of SYN-010 in IBS-C [Phase 2]
Phase 2 trial update for SYN-010 in irritable bowel syndrome with constipation (IBS-C) has been terminated; results posted in 2021.
-
FDA approval · 2021-05-19FDA Approved: IBSRELA — Supplemental Application (Ardelyx, Inc.)
The FDA approved a supplemental application for IBSRELA (tenapanor hydrochloride) from Ardelyx, Inc., likely updating labeling or expanding …
-
FDA approval · 2021-04-12FDA Approved: LINZESS — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Linzess (linaclotide) from Allergan, Inc., to update/expand its label.
-
FDA approval · 2021-03-05FDA Approved: IBSRELA — Supplemental Application (Ardelyx, Inc.)
Ardelyx submitted a supplemental application to the FDA for IBSRELA (tenapanor hydrochloride) related to its labeling for irritable bowel sy…
-
FDA approval · 2021-02-10FDA Approved: TRULANCE IMMEDIATE RELEASE — Supplemental Application (Salix Pharmaceuticals Inc.)
The FDA approved a supplemental application for Trulance Immediate Release (plecanatide) submitted by Salix Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2020-12-28Clinical Trial Update: A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation [Phase 2]
Phase 2 clinical trial evaluating multiple oral doses of linaclotide in children aged 7-17 with irritable bowel syndrome with constipation; …
-
FDA approval · 2020-11-30FDA Approved: LUBIPROSTONE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
The FDA approved a supplemental application for Lubiprostone submitted by Dr. Reddy's Laboratories, updating labeling under NDA 021908.
-
CLINICAL_TRIALS trial_result · 2020-11-16Clinical Trial Update: A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) [Phase 3]
Phase 3 trial of linaclotide 290 μg in irritable bowel syndrome with constipation has completed; results posted in 2020.
-
FDA approval · 2020-10-29FDA Approved: TRULANCE IMMEDIATE RELEASE — Supplemental Application (Salix Pharmaceuticals Inc.)
FDA approved a supplemental application to introduce an immediate-release formulation of Trulance (plecanatide) produced by Salix Pharmaceut…
-
FDA approval · 2020-09-22FDA Approved: LINZESS — Supplemental Application (Allergan, Inc.)
The FDA approved Allergan's supplemental application for Linzess (linaclotide), submitted by Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2020-08-06Clinical Trial Update: SAT vs Escitalopram for Rectal Hypersensitivity [Phase 2]
Phase 2 trial update comparing SAT to escitalopram for rectal hypersensitivity in IBS-C; study completed.
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) [Phase 2]
Phase 2 trial update for linaclotide in irritable bowel syndrome with constipation has completed with results posted.
-
FDA approval · 2019-09-12FDA Approved: IBSRELA — Original Application (Ardelyx, Inc.)
The FDA approved IBSRELA (tenapanor hydrochloride) in an original NDA for the treatment of irritable bowel syndrome with constipation. This …
-
CLINICAL_TRIALS research · 2019-08-22Clinical Trial Update: An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation [Phase 4]
Open-label, long-term Phase 4 study assessing immunogenicity ofLinaclotide (LINZESS) in adults with irritable bowel syndrome with constipati…